Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31367989 | 0.90 | PIM1 (0.39) | PIM1NLRP3MEN1KMT2AHSD17B10 | |
| SCHEMBL31368006 | 0.86 | NLRP3 (0.42) | PIM1NLRP3MEN1CYP1A2CYP2C19 | |
| SCHEMBL31368007 | 0.86 | NLRP3 (0.42) | PIM1NLRP3MEN1CYP1A2CYP2C19 | |
| SCHEMBL31367996 | 0.85 | PDE2A (0.31) | — | |
| SCHEMBL31367980 | 0.84 | NLRP3 (0.42) | PIM1NLRP3MEN1CYP1A2CYP2C19 | |
| SCHEMBL31367977 | 0.76 | NLRP3 (0.45) | PIM1NLRP3MEN1KMT2AHSD17B10 | |
| SCHEMBL31367967 | 0.76 | NLRP3 (0.45) | PIM1NLRP3MEN1KMT2AHSD17B10 | |
| SCHEMBL31367984 | 0.76 | PIM1 (0.32) | PIM1MEN1KMT2AHSD17B10 | |
| SCHEMBL31367994 | 0.74 | ADORA1 (0.42) | MEN1CYP1A2CYP2C19KMT2AGFER | |
| SCHEMBL31368000 | 0.73 | PDE2A (0.44) | MEN1CYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092051-A1 | NLRP3 MODULATORS AND USE THEREOF | Bioentropy Inc. (US) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092051-A1 | NLRP3 MODULATORS AND USE THEREOF | NLRP3, NLRP1, NOD1 | PIM1 3046/4885NLRP3 1/4885MEN1 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.